Trial Profile
A prospective, open-labelled clinical trial to evaluate the efficacy of intravitreal aflibercept for the treatment of treatment resistant macular oedema secondary to retinal vein occlusion
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Jan 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Retinal oedema
- Focus Therapeutic Use
- 11 Jan 2018 Status changed from not yet recruiting to recruiting.
- 26 Oct 2017 New trial record